Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714726 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT01714726 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 121 participants.
The verdict
NCT01714726, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection in open-label period
Interventions
- DRUG placebo
- DRUG MEDI2070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2016-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714726
The ClinicalTrials.gov registry entry for NCT01714726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01714726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01714726 about?
NCT01714726 is a clinical study titled "Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.". The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection in open-label period
What is the current status of trial NCT01714726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2013-02-01. Estimated completion is 2016-12-14.
What interventions are being tested in trial NCT01714726?
The interventions under investigation include: placebo (DRUG), MEDI2070 (DRUG).
Who is sponsoring clinical trial NCT01714726?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.